Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Recommendation of “Buy” from Analysts

Shares of Aura Biosciences, Inc. (NASDAQ:AURA) have been assigned an average rating of “Buy” from the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $23.00.

A number of equities analysts have issued reports on AURA shares. HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of Aura Biosciences in a report on Thursday, November 14th. Scotiabank raised their price target on Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a report on Friday, October 18th. BTIG Research boosted their price objective on Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research report on Friday, October 18th. Finally, Cowen reaffirmed a “buy” rating on shares of Aura Biosciences in a research report on Friday, October 18th.

Insider Activity at Aura Biosciences

In related news, insider Los Pinos Elisabet De sold 15,955 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the transaction, the insider now owns 304,692 shares in the company, valued at $2,336,987.64. This represents a 4.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Janet Jill Hopkins sold 11,822 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.36, for a total transaction of $110,653.92. Following the sale, the insider now owns 151,693 shares in the company, valued at $1,419,846.48. This trade represents a 7.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 38,531 shares of company stock worth $345,454 in the last three months. 5.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Aura Biosciences

A number of institutional investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. raised its stake in shares of Aura Biosciences by 2.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock worth $1,233,000 after buying an additional 3,612 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in Aura Biosciences by 14.6% during the second quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock worth $487,000 after acquiring an additional 8,194 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in Aura Biosciences in the fourth quarter worth about $87,000. Renaissance Technologies LLC lifted its holdings in Aura Biosciences by 26.3% in the 2nd quarter. Renaissance Technologies LLC now owns 72,100 shares of the company’s stock valued at $545,000 after acquiring an additional 15,000 shares during the last quarter. Finally, American Century Companies Inc. acquired a new position in shares of Aura Biosciences in the 2nd quarter worth approximately $119,000. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Aura Biosciences Trading Down 2.6 %

AURA stock opened at $7.89 on Friday. The stock’s 50 day simple moving average is $8.38 and its 200 day simple moving average is $8.92. Aura Biosciences has a 12-month low of $6.63 and a 12-month high of $12.38. The firm has a market cap of $394.11 million, a P/E ratio of -4.56 and a beta of 0.30.

Aura Biosciences (NASDAQ:AURA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.02. On average, research analysts forecast that Aura Biosciences will post -1.67 EPS for the current fiscal year.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.